Condition: Hepatocellular Carcinoma Non-resectable · Cholangiocarcinoma Non-resectable · Liver Metastases · Sponsor: Tianjin Medical University Cancer Institute and Hospital
This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.
This description comes directly from the study's public registry record.
Haipeng Yu · 022-23340123 · jieruke@163.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical University Cancer Institute and Hospital | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06487663